On September 5, 2022 CellOrigin Biotech (Hangzhou) Co., Ltd. reported that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary ‘off-the-shelf’ iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy (Press release, Qilu Pharmaceutical, SEP 5, 2022, View Source [SID1234619124]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This collaboration takes the advantages from both parties by integrating complementary technologies and expertise as well as combining industry-leading R&D, manufacture and marketing capabilities.Both parties will collaborate on new drug development and commercialization, and will push CAR-iMAC pipelines forward to clinical trials.
‘Innovation, and bringing the best products to benefit patients are the core values we both appreciate’, said Dr. Jin Zhang, the co-founder of CellOrigin Biotech and a principle investigator of Zhejiang University, ‘that’s something that brings us together’.
‘We are excited to collaborate with Qilu Pharmaceutical because of its prestige in the Chinese pharmaceutical industry as well as its successful track record in new drug discovery. We (CellOrigin) will keep seeking other potential industry collaborators, jointly exploring and developing innovative anti-tumor drugs, and benefiting more cancer patients’ said Dr. Tong Jiansong, Chief Executive Office at CellOrigin Biotech.
‘CellOrigin is an outstanding startup with a strong research background and valuable industry experience. It has focused on original techniques in cell therapy and gained rich expertise in GMP manufacture. It is an ideal strategic partner for novel cell therapy and it is our pleasure to collaborate with such a great biotech company.’ said Qilu Pharmaceutical.